BMY

Bristol-Myers Squibb Company

Healthcare

Congressional Trades

102

by 16 members

Ticker disclosure brief

Congressional disclosure records for BMY

A ticker-first view of recent disclosures, reported ranges, filing lags, party aggregates, federal awards, lobbying records, and source-linked receipts.

Latest receipt

Ro Khanna

SELL · 2026-06-16

Largest range

$15K – $50K

Mike Kelly

Longest observed gap

318d

Valerie Hoyle

Highest 30d vs SPY

26.0%

Ro Khanna

Purchase rows

42%

Sale rows

55%

Disclosed midpoint

$1.2M

range estimate

Unique Traders

members

Disclosure timing method

Observed filing gaps are not notice-date findings

The reporting deadline is the earlier of 30 days after notice or 45 days after the transaction. Public disclosure rows provide transaction and filing dates, but do not establish when a member received notice. PoliWealth therefore marks only transaction-to-filing gaps over 45 days as an apparent delay for review; 31–45 day gaps are not labeled late from transaction date alone.

Open >45-day tracker Official rule ↗

Party Breakdown

Democrats68 · 67%

Republicans34 · 33%

Federal awards

all →

2026-07-07$138K
Department of Veterans Affairs
POMALYST 2 MG, 3 MG,4 MG
2026-07-07$11K
Department of Veterans Affairs
POMALYST 3 MG
2026-06-30$364K
Department of Veterans Affairs
EMERGENCY BREYANZI
2026-06-26$12K
Department of Veterans Affairs
PATIENT MEDICATION - THALIDOMIDE 100MG - SHIP TO BALTIMORE VA MEDICAL CENTER PHARMACY.
2026-06-18$16K
Department of Veterans Affairs
POMALIDOMIDE(POMALYST) 4MG CAP
2026-06-16$364K
Department of Veterans Affairs
BREYANZI CAR T - TRANSPLANT
2026-06-16$364K
Department of Veterans Affairs
BREYANZI CAR T
2026-06-15$11K
Department of Veterans Affairs
POMALYST 3 MG
2026-06-11$17K
Department of Veterans Affairs
POMALYST 2 MG
2026-06-02$364K
Department of Veterans Affairs
BREAYNAZI FOR CAR-T TRANSPLANT MEDICATION

Lobbying filings

all →

2026-07-09$60K
BRISTOL-MYERS SQUIBB COMPANY
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to the 340B program. Issues related to FDA regulation of pharmaceuticals.
2026-04-20$1.3M
BRISTOL-MYERS SQUIBB COMPANY
H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.7391, CHC Drug Pricing Protection Act H.R.5509, Safe Step Act Issues related to biosimilars reimbursement issues Clinical Trial Modernization Act Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions Discussions regarding OECD implementation Intellectual Property Reform concerning bio-pharmaceutical industry International Reference Pricing/Most Favored Nation, including all bio-pharmaceutical issues
2026-04-20$80K
BRISTOL-MYERS SQUIBB COMPANY
340B Reform, FDA drug approvals, monitoring Food is Medicine initiatives, importation of biopharmaceutical products, pharmaceutical supply chain. Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation. Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues. H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies.
2026-04-20$80K
BRISTOL-MYERS SQUIBB
Policies related to the Most Favored Nation Drug Pricing Model Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act
2026-04-20$60K
BRISTOL-MYERS SQUIBB
Value of prescription drugs and patient access Issues related to Medicaid, Medicare Parts B & D, MFN U.S. Competitiveness issues
2026-04-20$60K
BRISTOL-MYERS SQUIBB COMPANY
Issues related to prescription drugs Issues related to prescription drugs; Issues related to Senate Finance Dear Colleague process
2026-04-20$50K
BRISTOL-MYERS SQUIBB COMPANY
Biosimilars reimbursement issues. Supply Chain Issues. Pharmacy Benefit Manager Reform. Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. 340B Program.
2026-04-20$40K
BRISTOL-MYERS SQUIBB
Issues regarding approved and pipeline products, and related policy. 340 program issues. Issues regarding approved and pipeline products, and related policy. Issues regarding approved and pipeline products, and related policy.
2026-04-20$30K
BRISTOL-MYERS SQUIBB COMPANY
Education about the value of biopharmaceutical innovation and related issues.
2026-04-20$0
BRISTOL-MYERS SQUIBB COMPANY
Issues related to biosimilars reimbursement, supply chain and Medicare/Medicaid payment reform. Issues related to biosimilars reimbursement, supply chain and Medicare/Medicaid payment reform.

Loading trade analytics…

All Disclosed Trades

Page 5 · 2 of 102 shown

Date	Member	Action	Amount	Observed Gap	Receipt
2018-12-28	DSheldon Whitehouse	SELL	$15K – $50K	1704dApparent delay	receipt →
2020-11-25	DRick Larsen	BUY	$1K – $15K	904dApparent delay	receipt →

← Newer trades

“Observed gap” is the calendar distance from transaction date to filing date; only gaps over 45 days receive an apparent-delay marker.